Japan initiates market authorization of weight‐loss drug semaglutide under universal health coverage, but with stringent prescription restrictions-Reference-Cited by-同舟云学术

Japan initiates market authorization of weight‐loss drug semaglutide under universal health coverage, but with stringent prescription restrictions

Published:2024-05-15 Issue:8 Volume:26 Page:3006-3008
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Hakariya Hayase¹²^ORCID,Ohnishi Mutsuko³,Tanimoto Tetsuya⁴^ORCID

Affiliation:

1. Interfaculty Institute of Biochemistry University of Tuebingen Tuebingen Germany

2. Institute for Pharmaceutical and Social Health Sciences Kyoto Japan

3. Medical Governance Research Institute Tokyo Japan

4. Navitas Clinic Tokyo Japan

Funder

Toyobo Biotechnology Foundation

Publisher

Wiley

Reference15 articles.

1. Pharmaceutical and Medical Devices Agency Japan.Review report of semaglutide for obesity. February 6 2024 [in Japanese] [cited February 22 2024].https://www.pmda.go.jp/drugs/2023/P20230303002/620023000_30500AMX00105000_A100_1.pdf

2. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults

3. Trends and Disparities in Adult Body Mass Index Across the 47 Prefectures of Japan, 1975–2018: A Bayesian Spatiotemporal Analysis of National Household Surveys

4. Ministry of Health Labour and Welfare Japan.Notes on the establishment of guidelines for the promotion of appropriate use of semaglutide (genetic recombination) preparation for the indication of obesity. November 21 2023 [in Japanese] [cited February 22 2024].https://www.mhlw.go.jp/content/001169796.pdf?fbclid=IwAR1FvvqM7vcI25vVDeP8W28B8KUfUghSkbTs4SiN6K5QlpRPi54‐UyWfc8Q

5. National Consumer Affairs Center of Japan.Telemedicine trouble for slimming purposes; “Subscription trouble” where diabetes drugs are prescribed off‐label for several months for the purpose of weight loss. December 20 2023 [in Japanese] [cited February 22 2024].https://www.kokusen.go.jp/news/data/n-20231220_1.html